'Next Science’s initial sales focus will be the US orthopaedic surgery market of 5.3M surgeries per year in 20104; a market opportunity of over $1B per annum.'
$189 to stop infections in patients seems like a no brainer to me.
Of course the patient will probably end nd up paying $1,000+ in the US healthcare system!
Ann: XPerience No Rinse Antimicrobial Solution cleared by FDA, page-2
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $58.43M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $42.76K | 213.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18228 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 12000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| NXS (ASX) Chart |